NIMG-57. SERIAL HYPERPOLARIZED 13C PYRUVATE AND 1H METABOLIC IMAGING IN RECURRENT HIGH-GRADE GLIOMA. Read more about NIMG-57. SERIAL HYPERPOLARIZED 13C PYRUVATE AND 1H METABOLIC IMAGING IN RECURRENT HIGH-GRADE GLIOMA.
NIMG-33. TUMOR GROWTH AND MRI TRAJECTORIES IN GRADE II AND III GLIOMA. Read more about NIMG-33. TUMOR GROWTH AND MRI TRAJECTORIES IN GRADE II AND III GLIOMA.
CBMT-36. INITIAL EXPERIENCE WITH HYPERPOLARIZED [2-13C]PYRUVATE MR IMAGING IN PATIENTS WITH IDH-MUTANT GLIOMA. Read more about CBMT-36. INITIAL EXPERIENCE WITH HYPERPOLARIZED [2-13C]PYRUVATE MR IMAGING IN PATIENTS WITH IDH-MUTANT GLIOMA.
CBMT-26. SERIAL CHARACTERIZATION OF HYPERPOLARIZED [1-13C]PYRUVATE METABOLISM IN PATIENTS WITH GLIOMA AND THE INFLUENCE OF BEVACIZUMAB. Read more about CBMT-26. SERIAL CHARACTERIZATION OF HYPERPOLARIZED [1-13C]PYRUVATE METABOLISM IN PATIENTS WITH GLIOMA AND THE INFLUENCE OF BEVACIZUMAB.
GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA Read more about GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA
EGFR amplification status for clinical trial inclusion: where do we draw the line? Read more about EGFR amplification status for clinical trial inclusion: where do we draw the line?
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Read more about Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
Barriers to accrual and enrollment in brain tumor trials. Read more about Barriers to accrual and enrollment in brain tumor trials.
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. Read more about Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
DIPG-31. FEASIBILITY OF HYPERPOLARIZED 13C METABOLIC IMAGING IN PEDIATRIC PATIENTS WITH DIPG AND OTHER CNS CANCERS. Read more about DIPG-31. FEASIBILITY OF HYPERPOLARIZED 13C METABOLIC IMAGING IN PEDIATRIC PATIENTS WITH DIPG AND OTHER CNS CANCERS.
